Company / R&D Expense
Fulgent Genetics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$53.9M
FY2025
5-year range
$6.5M / $53.9M
FY2021-FY2025
Trend
+10.4%
vs FY2024
Sector context
#78 of 110
Health Care
What the data says
At $54M, Fulgent Genetics, Inc.'s r&d expense ranks #78 of 110 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $7M in FY2021 to $54M in FY2025.
Based on SEC 10-K filings.
$54M in FY2025 with a 5-year CAGR of +36.0%.
Improved from $24M to $54M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +67.0%
- 5-Year CAGR
- +36.0%
- 10-Year CAGR
- -
Sector benchmark
#78 of 110 in Health CareTop 71% of 110This company $53.9M Sector average $298.2M
▼
-81.9% below sector average
Key checks
Key Insights
- Fulgent Genetics, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +36.0%, indicating consistent growth.
- In FY2025, r&d expense increased 10.4% year-over-year.
- Ranks #78 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.9M | +10.4% |
| FY2024 | $48.8M | +101.6% |
| FY2023 | $24.2M | +109.1% |
| FY2022 | $11.6M | +77.1% |
| FY2021 | $6.5M | -43.5% |
| FY2020 | $11.6M | +109.3% |
| FY2019 | $5.5M | +31.0% |
| FY2018 | $4.2M | +0.0% |
| FY2017 | $4.2M | +710.6% |
| FY2016 | $521.0K | -88.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026